

![]() |
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9 |
|
Authors | ![]() | |
Published in | EJNMMI Research. 2018, vol. 8, no. 1, p. 108 | |
Abstract | Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast. This study presents the first human dosimetry of 68Ga-NODAGA-MJ9 in the first five consecutive patients with recurrent prostate cancer included in a dual-tracer positron emission tomography (PET) protocol. Five male patients with biochemical relapse of prostate adenocarcinoma underwent four whole-body time-of-flight PET/CT scans within 2 h after tracer injection. To be used as input in OLINDA/EXM 2.0, time-integrated activity coefficients were derived from manually drawn regions of interest over the following body regions: brain, thyroid, lungs, heart, liver, gallbladder, spleen, stomach, kidneys, adrenals, red marrow, pancreas, intestines, urinary bladder and whole body. Organ absorbed doses and effective dose (ED) were calculated with OLINDA/EXM 2.0 using the NURBS voxelized phantoms adjusted to the ICRP-89 organ masses and ICRP103 tissue-weighting factors. Additional absorbed dose estimations were performed with OLINDA/EXM 1.1 to be comparable with similar previous publications. | |
Keywords | 68Ga-NODAGA-MJ9 — Biochemical relapse — Bombesin — Dosimetry — GRP antagonist — Gastrin-releasing peptide receptor — OLINDA/EXM — PET/CT — Prostate cancer — Theranostics | |
Identifiers | PMID: 30543050 | |
Full text | ||
Structures | ||
Research group | Laboratoire de neuroimagerie et de traceurs moléculaires innovants (984) | |
Citation (ISO format) | GNESIN, Silvano et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9. In: EJNMMI Research, 2018, vol. 8, n° 1, p. 108. doi: 10.1186/s13550-018-0462-9 https://archive-ouverte.unige.ch/unige:126250 |